The spacecraft reached an altitude of nearly 130 miles before landing in the Indian Ocean as planned. Photo via spacex.com

SpaceX’s mega Starship rocket completed its first full test flight Thursday, returning to Earth without exploding after blasting off from Texas.

It was the fourth launch of the world’s biggest and most powerful rocket, standing nearly 400 feet (121 meters) tall. The three previous flight demos ended in explosions. This time, the rocket and the spacecraft managed to splash down in a controlled fashion, making the hourlong flight the longest and most successful yet.

“Despite loss of many tiles and a damaged flap, Starship made it all the way to a soft landing in the ocean!” SpaceX CEO Elon Musk said via X.

Starship was empty as it soared above the Gulf of Mexico and headed east on a flight to the Indian Ocean. Within minutes, the first-stage booster separated from the spacecraft and splashed into the gulf precisely as planned, after firing its engines.

The spacecraft reached an altitude of nearly 130 miles (211 kilometers), traveling at more 16,000 mph (26,000 kph), before beginning its descent. Live views showed parts of the spacecraft breaking away during the intense heat of reentry, but a cracked camera lens obscured the images.

The spacecraft remained intact enough to transmit data all the way to its targeted splashdown site in the Indian Ocean.

It was a critical milestone in the company’s plan to eventually reuse the rocket that NASA and Musk are counting on to get humanity to the moon and then Mars.

“What a show it has been,” SpaceX launch commentator Kate Tice said from Mission Control at company headquarters in California.

SpaceX came close to avoiding explosions in March, but lost contact with the spacecraft as it careened out of space and blew up short of its goal. The booster also ruptured in flight, a quarter-mile above the gulf.

Last year’s two test flights ended in explosions shortly after blasting off from the southern tip of Texas near the Mexican border. The first one cratered the pad at Boca Chica Beach and hurled debris for thousands of feet (meters).

SpaceX upgraded the software and made some rocket-flyback changes to improve the odds. The Federal Aviation Administration signed off Tuesday on this fourth demo, saying all safety requirements had been met.

Starship is designed to be fully reusable. That’s why SpaceX wants to control the booster’s entry into the gulf and the spacecraft’s descent into the Indian Ocean — it’s intended as practice for planned future landings. Nothing is being recovered from Thursday’s flight.

NASA has ordered a pair of Starships for two moon-landing missions by astronauts, on tap for later this decade. Each moon crew will rely on NASA’s own rocket and capsule to leave Earth, but meet up with Starship in lunar orbit for the ride down to the surface.

SpaceX already is selling tourist trips around the moon. The first private lunar customer, a Japanese tycoon, pulled out of the trip with his entourage last week, citing the oft-delayed schedule.

SpaceX’s founder and CEO has grander plans: Musk envisions fleets of Starships launching people and the infrastructure necessary to build a city on Mars.

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”